Clinical Trials

70 enrolled

Neoplasms, Leukemia, Myeloid, Acute

NCT05283720 2026-03-03

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

Phase 2 Recruiting

496 enrolled

Phase 1 Active not recruiting

Leukemia, Hairy Cell, Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT06870487 2026-02-19

A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers

6 enrolled

DermatologicHead & NeckLymphoidOther hematologic neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Hodgkin Disease, Lung Neoplasms, Lymphoma, Non-Hodgkin, Melanoma, Neoplasm Metastasis, Neoplasms, Skin Neoplasms, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, Hematologic Neoplasms

NCT05618028 2026-02-12

Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets

150 enrolled

Lymphoma, Non-Hodgkin, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT04895436 2026-02-09

ReVenG

Phase 2 Recruiting

75 enrolled

Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell

NCT06756451 2026-01-30

This Study is a FIH Study Which is Required to Understand the PK Characteristics, MTD, RP2D and Safety Profile.

71 enrolled

Neoplasms, Hematologic Neoplasms

NCT05512390 2026-01-16

A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)

154 enrolled

Lymphoma, Follicular, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT06125795 2026-01-12

PROVIDENCE

132 enrolled

Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Patient Preference

NCT05215639 2025-12-10

VALOR

120 enrolled

Neoplasms, Leukemia, Myeloid, Acute

NCT03342144 2025-12-08

VeRVe

500 enrolled

Leukemia, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell

NCT04178317 2025-12-04

A Study of the Safety and Efficacy of Venetoclax for Participants With Chronic Lymphocytic Leukemia (CLL) Used in Routine Clinical Practice

14 enrolled

Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell

NCT05424562 2025-11-28

LIVEN

Active not recruiting

210 enrolled

Phase 1 Enrolling by invitation

Neoplasms, Leukemia, Myeloid, Acute

NCT06788509 2025-10-10

A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring

80 enrolled

LymphoidMyeloidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute

NCT02158858 2025-10-08

A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies

Phase 1/2 Completed

336 enrolled

MyeloidOther hematologic neoplasmOther neoplasm

Bone Marrow Diseases, Hematologic Diseases, Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Precancerous Conditions, Preleukemia, Thrombocythemia, Essential, Leukemia, Myeloid, Acute, Myelodysplastic-Myeloproliferative Diseases, Primary Myelofibrosis

NCT04161885 2025-10-06

VIALE-T

Phase 3 Terminated

465 enrolled

Neoplasms, Leukemia, Myeloid, Acute

NCT03162536 2025-09-08

ARQ 531-101

LymphoidOther hematologic neoplasmPlasma cellSarcoma

190 enrolled

Blood Protein Disorders, Cardiovascular Diseases, Hemorrhagic Disorders, Immune System Diseases, Immunoproliferative Disorders, Leukemia, Leukemia, Lymphoid, Lymphatic Diseases, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Waldenstrom Macroglobulinemia, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Recurrence, Vascular Diseases, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Hematologic Neoplasms, Hemostatic Disorders, Lymphoma, Mantle-Cell, Neoplasms, Plasma Cell, Dendritic Cell Sarcoma, Interdigitating

NCT05587049 2025-08-08

ESVECO

70 enrolled

Neoplasms, Leukemia, Myeloid, Acute

NCT05317494 2025-07-16

SURVIVE

100 enrolled

Neoplasms, Leukemia, Myeloid, Acute

NCT05555979 2025-06-29

ELECTRIC

56 enrolled

Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell

NCT05768269 2025-06-25

A Study for Participants Previously Treated With Century Therapeutics Cellular Therapy Product

375 enrolled

LymphoidMyeloidOther hematologic neoplasm

Neoplasms, Hematologic Neoplasms

NCT04996875 2025-05-30

APEX

Phase 2 Recruiting

140 enrolled

Hematologic Diseases, Hypersensitivity, Immune Complex Diseases, Immune System Diseases, Leukemia, Leukemia, Mast-Cell, Leukemia, Myeloid, Mastocytosis, Myeloproliferative Disorders, Neoplasms, Neoplasms by Site, Neoplasms, Connective Tissue, Skin Diseases, Soft Tissue Neoplasms, Urticaria Pigmentosa, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Mastocytosis, Systemic

NCT02494258 2025-05-22

A Study to Evaluate Long-term Safety of CC-486 (Oral Azacitidine) in Subjects With Hematological Disorders

Phase 2 Completed

5 enrolled

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmSarcomaThoracic

Hematologic Diseases, Neoplasms, Hematologic Neoplasms

NCT05179824 2025-05-06

Tempus Priority Study: A Pan-tumor Observational Study

Active not recruiting

1,000 enrolled

Bile Duct Neoplasms, Urinary Bladder Neoplasms, Bone Neoplasms, Brain Neoplasms, Breast Neoplasms, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Fallopian Tube Neoplasms, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Laryngeal Neoplasms, Leukemia, Liver Neoplasms, Lung Neoplasms, Lymphoma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Skin Neoplasms, Stomach Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms

NCT04813263 2025-04-27

Study of Oral Venetoclax Tablets to Evaluate Adverse Events and Change in Disease Activity in Participants of Any Age With Acute Myeloid Leukemia

424 enrolled

Neoplasms, Leukemia, Myeloid, Acute

NCT06058741 2025-04-22

VERO

Active not recruiting

150 enrolled

Neoplasms, Leukemia, Myeloid, Acute

NCT04742101 2025-04-11

Phase I/II Trial of S65487 Plus Azacitidine in Acute Myeloid Leukemia

57 enrolled

Phase 1 Active not recruiting

Neoplasms, Leukemia, Myeloid, Acute

NCT05206357 2025-04-08

Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab

17 enrolled

Leukemia, Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT05282108 2025-03-26

CARCML

240 enrolled

Leukemia, Neoplasms, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Hematologic Neoplasms

NCT02834390 2025-03-05

Study of Quizartinib in Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)

Phase 1 Completed

7 enrolled 16 charts

Neoplasms, Leukemia, Myeloid, Acute

NCT02636855 2025-03-04

Screening Protocol for Tumor Antigen Expression Profiling and HLA Typing for Eligibility Determination

9,122 enrolled

Phase 1 Active not recruiting

Neoplasm Metastasis, Neoplasms, Hematologic Neoplasms

NCT04041050 2025-02-14

A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm

85 enrolled

Myeloproliferative Disorders, Neoplasms, Polycythemia Vera, Thrombocythemia, Essential, Leukemia, Myelomonocytic, Chronic, Primary Myelofibrosis

NCT02743546 2025-02-03

Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in Lymphoma

Phase 1 Withdrawn

Bronchiolitis Obliterans Syndrome, Lymphoma, Follicular, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT04305444 2025-01-08

Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas

Phase 2 Terminated

55 enrolled

Leukemia, Lymphatic Diseases, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT04310592 2024-12-12

CYNK001AML01

27 enrolled

Hematologic Diseases, Leukemia, Leukemia, Myeloid, Neoplasms, Neoplasms by Histologic Type, Leukemia, Myeloid, Acute, Neoplasm, Residual, Hematologic Neoplasms

NCT05302037 2024-11-22

ANGELICA

12 enrolled

Neoplasms, Recurrence, Hematologic Neoplasms

NCT03155191 2024-11-20

TBI-1501

21 enrolled

Immune System Diseases, Leukemia, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Experimental, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03648372 2024-11-19

A Study of TAK-981 in People With Advanced Solid Tumors or Cancers in the Immune System

Phase 1/2 Terminated

109 enrolled 54 charts

Phase 2 Active not recruiting

Lymphoma, Neoplasms, Hematologic Neoplasms

NCT03678883 2024-11-07

9-ING-41 in Patients with Advanced Cancers

350 enrolled

BreastCNSGastrointestinalGenitourinaryLymphoidOther hematologic neoplasmSarcomaThoracic

Bone Neoplasms, Breast Neoplasms, Glioma, Kidney Neoplasms, Lung Neoplasms, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms, Leukemia-Lymphoma, Adult T-Cell

NCT03837899 2024-10-29

Durvalumab and Tremelimumab for Pediatric Malignancies

50 enrolled 59 charts

Neoplasms, Hematologic Neoplasms

NCT03814005 2024-09-05

A Study of Pevonedistat in People With Blood Cancers or Solid Tumors With Kidney or Liver Problems

Phase 1 Completed

17 enrolled 33 charts

Liver Diseases, Myelodysplastic Syndromes, Neoplasms, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Renal Insufficiency

NCT03530683 2024-09-03

A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma

LymphoidOther hematologic neoplasmPlasma cell

189 enrolled

Leukemia, Lymphoma, Multiple Myeloma, Neoplasms, Leukemia, Myeloid, Acute, Lymphoma, Large B-Cell, Diffuse, Neoplasms, Plasma Cell

NCT03557619 2024-08-29

A Study to Assess the Effect of Venetoclax on Ethinyl Estradiol and Levonorgestrel in Female Participants With Different Hematological Malignancies

12 enrolled

Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Hematologic Neoplasms

NCT03406156 2024-08-06

A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy

Phase 3 Completed

120 enrolled 14 charts

Chromosome 17 deletion, Neoplasms, Tumor Lysis Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02520427 2024-07-31

A Phase 1 Study of AMG 330 in Subjects With Myeloid Malignancies

95 enrolled 47 charts

Phase EARLY_PHASE1 Recruiting

Myelodysplastic Syndromes, Neoplasms, Leukemia, Myeloid, Acute

NCT05707325 2024-07-24

Reboot-101

30 enrolled

Neoplasms, Hematologic Neoplasms

NCT05933070 2024-07-18

LAUREL

2 enrolled

Myelodysplastic Syndromes, Neoplasms, Leukemia, Myeloid, Acute

NCT02384954 2024-07-03

QUILT-3.002: N-803 in Patients With Relapse/Refractory iNHL in Conjunction With Rituximab

Phase 1/2 Terminated

43 enrolled 15 charts

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone

NCT01611142 2024-06-17

Study of KW-0761 (Mogamulizumab) in Subjects With Previously Treated Peripheral T-cell Lymphoma (PTCL)

Phase 2 Completed

38 enrolled